A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)

ClinicalTrials.gov ID: NCT03592472

Public ClinicalTrials.gov record NCT03592472. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 16, 2026, 5:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Phase 3, Double-blind, Placebo-controlled Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma(RENAVIV)

Study identification

NCT ID: NCT03592472
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: Xynomic Pharmaceuticals, Inc.; Industry
Enrollment: 413 participants

Conditions and interventions

Conditions

Renal Cell Carcinoma

Interventions

Abexinostat Drug
Pazopanib Drug
Placebo Other

Drug · Other

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 16, 2018
Primary completion: Dec 29, 2026
Completion: Jun 29, 2028
Last update posted: Apr 12, 2025

2018 – 2028

United States locations

U.S. sites: 14
U.S. states: 11
U.S. cities: 13

Facility	City	State	ZIP	Site status
University Of UA Cancer Center(UACC)/DH-SJHMC	Phoenix	Arizona	85004	Withdrawn
University of California Davis Comprehensive Cancer Center	Sacramento	California	95817	Withdrawn
UCSF Helen Diller Family Comphrensive Cancer Center - Hemato	San Francisco	California	94158	Withdrawn
Norton Cancer Institute, Norton Healthcare Pavilion	Louisville	Kentucky	40202	Completed
Ochsner Clinic Foundation	New Orleans	Louisiana	70121	Completed
GU Research Network/Urology Cancer Center	Omaha	Nebraska	68130	Withdrawn
Nebraska Cancer Specialists	Omaha	Nebraska	68130	Completed
Northwell Health/Monter Cancer Center	Lake Success	New York	11042	Withdrawn
Mainstreet Physicans Care	Rochester	New York	14642	Completed
Precision Cancer Research/Dayton Physicians Network - Treatment	Kettering	Ohio	45409	Withdrawn
Oregon Health and Science University	Portland	Oregon	97239	Completed
St. Luke's Hospital	Easton	Pennsylvania	18045	Completed
HOPE Cancer Center of East Texas	Tyler	Texas	75701	Completed
Medical Oncology Associates, PS (dba Summit Cancer Centers)	Spokane	Washington	99208	Withdrawn

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 24 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03592472, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 12, 2025 · Synced May 16, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03592472 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →